This post continues the discussion of optimization opportunities for GC labs, focusing on headspace sampling for the efficient and automated analysis of vo...
Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire Pheno...
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation. Custo...
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial inte...
Highlights: Reported revenue of $1.67 billion declined 2.7% year-over-year, and decreased 2.3% on a core(1) basis. GAAP net income of $111 millio...
Under the agreement, AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to perform process transfer, process opti...
– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform – – Gilead Re...
-Sequel, a startup, dedicated to engineering better health and wellness experiences for women, today announced that its breakthrough spiral tampon has rece...
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Part...
GE HealthCare’s smart phone-sized Portrait Mobile frees the patient from the hospital bed while providing continuous monitoring of vital signs, usi...
The approval of ELREXFIO (elranatamab-bcmm) is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study EL...
FDA also accepted the "safety first" staggered parallel clinical design of ZM008 combination arm with Pembrolizumab to benefit a wider range of patients wh...
Company Activates Additional Study Location to Expedite Enrollment Completion HLHS is a congenital birth defect in which the left ventricle (one of the pu...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
© 2025 Biopharma Boardroom. All Rights Reserved.
